WO2009089066A3 - Composés destinés à être utilisés dans le diagnostic et le traitement d'un mélanome, comprenant un mélanome métastasique, et procédés s'y rapportant - Google Patents
Composés destinés à être utilisés dans le diagnostic et le traitement d'un mélanome, comprenant un mélanome métastasique, et procédés s'y rapportant Download PDFInfo
- Publication number
- WO2009089066A3 WO2009089066A3 PCT/US2009/000179 US2009000179W WO2009089066A3 WO 2009089066 A3 WO2009089066 A3 WO 2009089066A3 US 2009000179 W US2009000179 W US 2009000179W WO 2009089066 A3 WO2009089066 A3 WO 2009089066A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- melanoma
- present
- well
- compounds
- novel
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- C07K14/68—Melanocyte-stimulating hormone [MSH]
- C07K14/685—Alpha-melanotropin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Optics & Photonics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention porte sur de nouveaux outils/composés de diagnostic non invasifs comprenant un peptide cyclique, le composé se liant à un récepteur de MSH pour imager et traiter des cancers, notamment un mélanome, y compris le mélanome métastasique in vivo. La présente invention représente une avancée nette dans la technique qui repose présentement sur une biopsie de tissu pour les diagnostics de ces cancers. Les nouvelles sondes d'imagerie sont capables de détecter des cellules de mélanome cancéreux, ainsi que leur étalement métastasique dans les tissus. Ceci représente un bond en avant dans le diagnostic et le traitement du mélanome, y compris le mélanome métastasique, à l'aide de techniques non-invasives d'imagerie moléculaire. Les nouvelles sondes de la présente invention seront également utiles pour amorcer une thérapie pour un mélanome ainsi que pour surveiller des réponses de patients à des traitements de chimiothérapie et autres interventions ou thérapies utilisées dans le traitement d'un mélanome/mélanome métastasique. Les composés selon la présente invention peuvent être utilisés en tant qu'outils de diagnostic pour un nombre de pathologies et de maladies ainsi qu'en tant qu'agents thérapeutiques pour traiter de telles pathologies et maladies.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/811,946 US8603435B2 (en) | 2008-01-10 | 2009-01-12 | Compounds and methods for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same |
US14/067,064 US9393330B2 (en) | 2008-01-10 | 2013-10-30 | Compounds for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same |
US15/186,764 US10265425B2 (en) | 2008-01-10 | 2016-06-20 | Compounds for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same |
US16/267,477 US11160887B2 (en) | 2008-01-10 | 2019-02-05 | Compositions for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1065208P | 2008-01-10 | 2008-01-10 | |
US61/010,652 | 2008-01-10 | ||
US12463508P | 2008-04-18 | 2008-04-18 | |
US61/124,635 | 2008-04-18 | ||
US12508708P | 2008-04-22 | 2008-04-22 | |
US61/125,087 | 2008-04-22 | ||
US12756108P | 2008-05-14 | 2008-05-14 | |
US61/127,561 | 2008-05-14 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/811,946 A-371-Of-International US8603435B2 (en) | 2008-01-10 | 2009-01-12 | Compounds and methods for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same |
US14/067,064 Division US9393330B2 (en) | 2008-01-10 | 2013-10-30 | Compounds for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009089066A2 WO2009089066A2 (fr) | 2009-07-16 |
WO2009089066A3 true WO2009089066A3 (fr) | 2009-10-22 |
Family
ID=40853702
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/000179 WO2009089066A2 (fr) | 2008-01-10 | 2009-01-12 | Composés destinés à être utilisés dans le diagnostic et le traitement d'un mélanome, comprenant un mélanome métastasique, et procédés s'y rapportant |
Country Status (2)
Country | Link |
---|---|
US (4) | US8603435B2 (fr) |
WO (1) | WO2009089066A2 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009089066A2 (fr) * | 2008-01-10 | 2009-07-16 | Stc.Unm | Composés destinés à être utilisés dans le diagnostic et le traitement d'un mélanome, comprenant un mélanome métastasique, et procédés s'y rapportant |
US8986651B2 (en) | 2009-11-30 | 2015-03-24 | Stc.Unm | Compounds with reduced ring size for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same |
US20130338033A1 (en) * | 2011-01-27 | 2013-12-19 | Virginia Commonwealth University | Diagnostic and Prognostic Markers for Metastasis |
US20180126013A1 (en) * | 2015-05-06 | 2018-05-10 | H.Lee Moffitt Cancer Center And Research Institute, Inc. | Radiotherapeutic and companion imaging agents to target mc1r |
US11541134B1 (en) | 2021-08-02 | 2023-01-03 | Rayzebio, Inc. | Stabilized compositions of radionuclides and uses thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991000111A1 (fr) * | 1989-06-23 | 1991-01-10 | Cancer Research Campaign Technology Limited | Agents de ciblage |
US5674839A (en) * | 1987-05-22 | 1997-10-07 | Competitive Technologies, Inc. | Cyclic analogs of alpha-MSH fragments |
US20080004213A1 (en) * | 2003-11-24 | 2008-01-03 | Clinuvel Pharmaceuticals Limited | Method of Inducing Melanogenesis in Humans With Mc1R Variant Alleles |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009089066A2 (fr) * | 2008-01-10 | 2009-07-16 | Stc.Unm | Composés destinés à être utilisés dans le diagnostic et le traitement d'un mélanome, comprenant un mélanome métastasique, et procédés s'y rapportant |
JP2009267366A (ja) | 2008-04-02 | 2009-11-12 | Nec Electronics Corp | 半導体記憶装置及びその製造方法 |
WO2011005380A2 (fr) * | 2009-06-12 | 2011-01-13 | Stc. Unm | Peptide hybride d'hormone stimulatrice des mélanocytes alpha conjuguées arg-gly-asp à utiliser dans le diagnostic et dans le traitement du mélanome, y compris le mélanome métastatique, et procédés afférents |
US8986651B2 (en) * | 2009-11-30 | 2015-03-24 | Stc.Unm | Compounds with reduced ring size for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same |
US9180214B1 (en) * | 2011-04-22 | 2015-11-10 | Stc.Unm | Gonadotropin-releasing hormone receptor-targeting peptides and their use to treat and diagnose cancer |
US9463255B1 (en) * | 2011-09-29 | 2016-10-11 | Stc.Unm | Radiolabeled alpha-melanocyte stimulating hormone hybrid peptide for melanoma targeting |
-
2009
- 2009-01-12 WO PCT/US2009/000179 patent/WO2009089066A2/fr active Application Filing
- 2009-01-12 US US12/811,946 patent/US8603435B2/en active Active
-
2013
- 2013-10-30 US US14/067,064 patent/US9393330B2/en active Active
-
2016
- 2016-06-20 US US15/186,764 patent/US10265425B2/en active Active
-
2019
- 2019-02-05 US US16/267,477 patent/US11160887B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5674839A (en) * | 1987-05-22 | 1997-10-07 | Competitive Technologies, Inc. | Cyclic analogs of alpha-MSH fragments |
WO1991000111A1 (fr) * | 1989-06-23 | 1991-01-10 | Cancer Research Campaign Technology Limited | Agents de ciblage |
US20080004213A1 (en) * | 2003-11-24 | 2008-01-03 | Clinuvel Pharmaceuticals Limited | Method of Inducing Melanogenesis in Humans With Mc1R Variant Alleles |
Non-Patent Citations (3)
Title |
---|
PAUL MCQUADE ET AL.: "Imaging of melanoma using 64Cu-and 86Y-DOTA-ReCCMSH(Arg11), a cyclized peptide analogue of a -MSH", JOURNAL OF MEDICAL CHEMISTRY, vol. 48, no. 8, 2005, pages 2985 - 2992 * |
YUBIN MIAO ET AL.: "111In-Labeled lactam bridge-cyclized a -Melanocyte Stimulating Hormone peptide-analogues for melanoma imaging.", BIOCONJUGATE CHEMISTRY, vol. 19, no. 2, 2008, pages 539 - 547 * |
YUBIN MIAO ET AL.: "Alpha-melanocyte stimulating hormone peptide-targeted melanoma imaging.", FRONTIERS IN BIOSCIENCE., vol. 12, 2007, pages 4514 - 4524 * |
Also Published As
Publication number | Publication date |
---|---|
WO2009089066A2 (fr) | 2009-07-16 |
US20190282716A1 (en) | 2019-09-19 |
US9393330B2 (en) | 2016-07-19 |
US11160887B2 (en) | 2021-11-02 |
US20110033380A1 (en) | 2011-02-10 |
US20140147385A1 (en) | 2014-05-29 |
US10265425B2 (en) | 2019-04-23 |
US8603435B2 (en) | 2013-12-10 |
US20160375158A1 (en) | 2016-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009151646A3 (fr) | Agents diagnostiques non invasifs et procédés de diagnostic d'une maladie infectieuse | |
WO2011066521A3 (fr) | Composés ayant une taille de cycle réduite destinés à être utilisés pour diagnostiquer et traiter un mélanome, y compris un mélanome métastatique et procédés associés | |
Campana et al. | Bleomycin-based electrochemotherapy: clinical outcome from a single institution’s experience with 52 patients | |
Whitmer et al. | High frequency deep brain stimulation attenuates subthalamic and cortical rhythms in Parkinson's disease | |
MX357819B (es) | Celulosa modificada a partir de fibra kraft química y métodos para elaborarla y su uso. | |
Weeks et al. | MRI-guided focused ultrasound (MRgFUS) to treat facet joint osteoarthritis low back pain—case series of an innovative new technique | |
Filonenko et al. | Photodynamic therapy of early esophageal cancer | |
WO2014205555A8 (fr) | Procédés et utilisations pour diagnostiquer et traiter le cancer de la prostate | |
WO2008008483A3 (fr) | Compositions basées sur dendrimères et procédés d'utilisation correspondants | |
WO2007126391A8 (fr) | Recherche d'états de sécheresse des muqueuses | |
WO2010022252A3 (fr) | Dispositif et procédé pour l'évaluation d'un médicament et traitement local | |
WO2004098389A3 (fr) | Dispositifs, systemes et procedes de mesure de bioimpedance de tissu cervical et procedes pour diagnostiquer et traiter un col de l'uterus humain | |
ATE493169T1 (de) | Medizinische vorrichtung zur bestimmung des herzzustands eines patienten, dem ein aktives implantat zur biventrikulären stimulation eingesetzt wurde | |
WO2009089066A3 (fr) | Composés destinés à être utilisés dans le diagnostic et le traitement d'un mélanome, comprenant un mélanome métastasique, et procédés s'y rapportant | |
WO2009009203A3 (fr) | Compositions à base de dendrimères et procédés pour les utiliser | |
WO2002032292A3 (fr) | Procedes pour la mise au point et l'utilisation d'agents diagnostiques et therapeutiques | |
WO2018064225A1 (fr) | Traitement des troubles de perte de contrôle | |
WO2011005380A3 (fr) | Peptide hybride d'hormone stimulatrice des mélanocytes alpha conjuguées arg-gly-asp à utiliser dans le diagnostic et dans le traitement du mélanome, y compris le mélanome métastatique, et procédés afférents | |
Haemmerich | Non-invasive image-guided targeted drug delivery | |
WO2009149166A3 (fr) | Procédés et compositions pour le diagnostic et le traitement de troubles prolifératifs | |
DE602004021722D1 (de) | Bei tumorbildgebung und krebsbehandlung als trägermittel für pharmazeutische verbindungen eingesetzte autoantikörper | |
WO2007022484A3 (fr) | Hemostase a induction acoustique et spectroscopie optique in vivo | |
Sanghar et al. | Efficacy of ultrasonography in the diagnosis of inflammatory swellings of odontogenic origin | |
Rak et al. | Upregulation of mitogen-activated protein kinase in ganglioglioma | |
Choi et al. | Magnetic Resonance Imaging Meets Fiber Optics: a Brief Investigation of Multimodal Studies on Fiber Optics-Based Diagnostic/Therapeutic Techniques and Magnetic Resonance Imaging |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09701391 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12811946 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09701391 Country of ref document: EP Kind code of ref document: A2 |